Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous EBV- and oncogene-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous EBV- and oncogene-specific cytotoxic T lymphocytes is an adoptive cell therapy developed by Sun Yat-Sen University Cancer Center for the treatment of nasopharyngeal carcinoma (NPC). This personalized immunotherapy involves the ex vivo expansion of a patient's own T cells, which are specifically primed to recognize and eliminate cells expressing Epstein-Barr virus (EBV) antigens, such as Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2), as well as other tumor-associated oncogenic proteins. Since EBV is a primary oncogenic driver in nearly all cases of non-keratinizing NPC, these targeted cytotoxic T lymphocytes (CTLs) are designed to provide a precise immune response against the malignancy. The therapy is primarily investigated for patients with stage IV or recurrent nasopharyngeal carcinoma who have limited options following standard chemotherapy.
- Other names
- autologous EBV- and oncogene-targeted cytotoxic T lymphocytesautologous EBV- and oncogene-targeted CTLsautologous Epstein-Barr virus and oncogene-targeted cytotoxic T lymphocytes
02
Targets
Epstein-Barr virus nuclear antigen family-derived peptide-HLA class I complexself-peptide–HLA (Host self-peptide–Human Leukocyte Antigen complex)Tumor oncogene-derived peptide–HLA class I complexEpstein-Barr virus latency/lytic antigen-derived peptide-HLA complexEpstein-Barr virus Latent Membrane Protein 1-derived peptide–HLA class I complexesEpstein-Barr virus latent membrane protein 2-derived peptide–HLA class I complex
Beyond the preview
Go deeper on autologous EBV- and oncogene-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous EBV- and oncogene-specific cytotoxic T lymphocytes.